Similar to EGFR, disrupting VEGFR signaling pathways has been commonly used as molecular target therapy for highly vascularised tumors, such as colorectal and hepatic cancer [96,97], lung cancer [98], and breast cancer [99]. The gene discussed is EGFR; the disease is liver cancer.